Insider purchasing activity has decreased as the earnings-reporting season begins, limiting trading opportunities. Noteworthy purchases have occurred in biotech and e-commerce, signaling potential confidence in stock price increases. Corporate insiders often buy shares expecting gains, particularly in volatile market conditions. For instance, CRISPR Therapeutics AG has seen a substantial rise of over 72% in the last 90 days, surpassing its 52-week high and outpacing major market indexes. Analysts predict further increases, reinforcing buy recommendations among investors.
A well-known adage reminds us that corporate insiders and 10% owners really only buy shares of a company because they believe the stock price will rise and they want to profit from it.
The share price is up over 72% in the past 90 days, and the stock has reached a 52-week high above $71. Shares are almost 20% higher than a year ago, outperforming the S&P 500 and the Nasdaq in that time.
Collection
[
|
...
]